Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to test the hypothesis that distal renal denervation (RDN) may delay or prevent the progressive decline of renal function in patients with type 2 diabetes mellitus and hypertension
Detailed Description: Diabetes mellitus and hypertension are two major causes of chronic kidney disease (CKD) that starts as subclinical decline in renal function that silently progresses to symptomatic advanced stages associated with irreversible significant damage of the kidney structure. Recent major improvements in pharmacotherapy of hypertension and diabetes have substantially reduced the prevalence of cardiovascular complications, yet, the frequency of CKD remains largely unchanged. Renal denervation is a new minimally invasive method to create regional blockade of the renal sympathetic nerves that is currently used as non-pharmacological therapy of hypertension. The CKD is likewise mediated by overactivity of renal sympathetic system so that RDN has strong potential to prevent development or progression of CKD. The new anatomically optimized distal RDN may have additional benefit in this regard. Denervation of the distal vessels involved in tonic regulation of renal blood should cause a significant drop in renal vascular resistance and proportional increase in blood and oxygen supply to the kidney preventing/reducing chronic hypoxia of renal tissue that is major mechanism of CKD. The aim of this study is to prove the aforementioned concept. For this purpose the eligible patients with type 2 diabetes mellitus and hypertension will undergo distal renal denervation performed using dedicated radiofrequency catheter Symplicity Spyral. The changes in the kidney function and structure as well as BPs (office and ambulatory) will be assessed at baseline, 6 and 12 months post-procedure
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Distal renal denervation | Experimental | The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anatomically optimized distal renal denervation | Procedure | Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter |
| Measure | Description | Time Frame |
|---|---|---|
| Change in estimated glomerular filtration rate renal function (eGFR) | eGFR calculated using CKD-EPI formula | from baseline to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in eGFR | eGFR calculated using CKD-EPI formula | from baseline 12 months |
| Change in office blood pressure levels (systolic/diastolic) | Blood pressure measurement performed by physician in office |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alla Falkovskaya, MD, PhD | Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences | Tomsk | 634012 | Russia |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Dec 8, 2025 | |
| Reset | Dec 23, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Dec 8, 2025 | Dec 23, 2025 | |||
| Jun 23, 2026 |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D006973 | Hypertension |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| from baseline to 6 months and 12 months |
| Change in ambulatory 24-hour blood pressure levels (24-h mean, daytime, nighttime; systolic/diastolic) | Mean values for respective periods calculated from ambulatory blood pressure monitoring performed using automatic measurement device | from baseline to 6 and 12 months |
| Change in cystatin C levels | blood analysis | from baseline to 6 and 12 months |
| Change in lipocalin 2 (NGAL) levels | blood analysis | from baseline to 6 and 12 months |
| Change in 24-hour urinary albumin excretion | urinalysis | from baseline to 6 and 12 months |
| Change in the cortical and medullary volume of the kidneys and their ratio according to MRI | Cortical and medullary volume measured using magnetic resonance imaging | from baseline to 12 months |
| Prognostic significance of baseline HbA1c value with regard to change in eGFR | Will be assessed from multiple regression model of linear dependence of change in eGFR on a number of independent variables including in addition to HbA1c also age, sex, baseline eGFR, and 24-h ambulatory systolic BP | from baseline to 6 and 12 months |
| Change in renal resistive index in a trunk | resistive index calculated using blood flow velocity on Doppler ultrasound | from baseline to 6 and 12 months |
| Change in peak linear blood flow velocity in the trunk and in segmental renal arteries | blood flow velocity assessed by Doppler flowmetry in the trunk of the renal arteries and in segmental renal arteries using averaged values | from baseline to 6 and 12 months |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |